MOG-CAR-Tregs cell therapy (Sangamo Therapeutics)

N/A

Report date: 2023/11/20 17:34:35

Base Information

Drug NameMOG-CAR-Tregs cell therapy (Sangamo Therapeutics)
Drug Alias NameMyelin Oligodendrocyte Glycoprotein (MOG)-CAR-Tregs cell therapy (Sangamo Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsMyelin-oligodendrocyte glycoprotein modulators
TargetsMyelin-oligodendrocyte glycoprotein
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSangamo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSangamo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A